Given that BEAMing is currently the most sensitive technology for ctDNA detection in plasma, and due to the very limited evidence on liquid biopsy in primary brain tumors, we hypothesized that BEAMing could allow for the detection of IDH mutations in the peripheral blood of patients with gliomas [32]. Here, IDH2 is linked to glioma.